Publications by authors named "Maria Lucia B Piruzeli"
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
E Wesley Ely Athimalaipet V Ramanan Cynthia E Kartman Stephanie de Bono Ran Liao Maria Lucia B Piruzeli
Lancet Respir Med
April 2022
Background: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation.
View Article and Find Full Text PDFEfficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Vincent C Marconi Athimalaipet V Ramanan Stephanie de Bono Cynthia E Kartman Venkatesh Krishnan Maria Lucia B Piruzeli
Lancet Respir Med
December 2021
Article Synopsis
- Baricitinib is a selective Janus kinase inhibitor being tested for its effectiveness and safety when combined with standard of care treatments for hospitalized adults with COVID-19.
- In a phase 3 trial, 1525 participants were randomly assigned to receive either baricitinib or a placebo for up to 14 days while receiving standard treatments like corticosteroids and antivirals.
- The study found that 27.8% of those on baricitinib and 30.5% on placebo progressed to severe outcomes, with no significant difference in effectiveness (p=0.18).